What is Nodality?
Nodality is at the forefront of revolutionizing drug discovery, therapeutic development, and precision medicine. The company's core innovation lies in its proprietary Single Cell Network Profiling (SCNP) platform, which delivers critical, clinically actionable information to overcome limitations in traditional research and development. SCNP provides deep insights into diseases and partner product candidates, applicable across the entire discovery and development lifecycle, including disease profiling, drug profiling, clinical development, and life cycle management. With a strong focus on immunology and oncology, including immuno-oncology, Nodality's expertise enables smarter spending decisions and supports a broad therapeutic landscape. The company has already established multi-year strategic collaborations with industry giants such as UCB Pharma S.A., Pfizer, and Johnson & Johnson, validating the power and applicability of its SCNP technology.
How much funding has Nodality raised?
Nodality has raised a total of $50.1M across 6 funding rounds:
Series A
$11.1M
Series B
$20M
Private Equity
$3.5M
Series C
$3.5M
Unspecified
$2M
Debt
$10M
Series A (2007): $11.1M with participation from Kleiner Perkins and TPG Biotechnology
Series B (2009): $20M led by Maverick Capital
Private Equity (2009): $3.5M, investors not publicly disclosed
Series C (2010): $3.5M featuring Maverick Capital, Kleiner Perkins, and TPG Growth
Unspecified (2010): $2M backed by Kleiner Perkins
Debt (2011): $10M with participation from Undisclosed
Key Investors in Nodality
Kleiner Perkins
Kleiner Perkins is a prominent venture capital firm based in Menlo Park, known for investing in early and growth-stage technology and life science companies. They provide capital and operational support from seed through IPO or acquisition.
Maverick Capital
Maverick Capital is an employee-owned hedge fund sponsor that invests in public equity markets and venture-backed biotechnology companies, based in Dallas, Texas.
TPG Growth
TPG Growth is part of TPG, a global investment firm managing alternative assets. They focus on supporting business growth across diverse industries, including healthcare and life sciences, through private equity and other investment strategies.
What's next for Nodality?
The recent major strategic investment in Nodality signals a critical phase of scaling and market penetration. With a substantial total funding base of $50.1M, the company is well-positioned to expand its SCNP platform's reach and deepen its impact on drug discovery and development. Future strategic initiatives will likely involve further enhancing its collaborative partnerships, potentially exploring new therapeutic areas beyond its current focus on immunology and oncology, and continuing to refine its technology for greater clinical utility. This infusion of capital is expected to fuel innovation, accelerate the translation of research into viable therapies, and solidify Nodality's position as a key player in precision medicine.
See full Nodality company page
